HRP20030652A2 - Method of treating of demyelinating diseases or conditions - Google Patents
Method of treating of demyelinating diseases or conditions Download PDFInfo
- Publication number
- HRP20030652A2 HRP20030652A2 HR20030652A HRP20030652A HRP20030652A2 HR P20030652 A2 HRP20030652 A2 HR P20030652A2 HR 20030652 A HR20030652 A HR 20030652A HR P20030652 A HRP20030652 A HR P20030652A HR P20030652 A2 HRP20030652 A2 HR P20030652A2
- Authority
- HR
- Croatia
- Prior art keywords
- hydrogen
- compound
- c6alkyl
- alkyl
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 50
- 208000016192 Demyelinating disease Diseases 0.000 title claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 208000020431 spinal cord injury Diseases 0.000 claims description 29
- 208000014674 injury Diseases 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 208000002193 Pain Diseases 0.000 claims description 15
- -1 benzyloxy, hydroxy Chemical group 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 102000004257 Potassium Channel Human genes 0.000 claims description 14
- 108020001213 potassium channel Proteins 0.000 claims description 14
- 230000003210 demyelinating effect Effects 0.000 claims description 13
- 210000003932 urinary bladder Anatomy 0.000 claims description 11
- 230000000903 blocking effect Effects 0.000 claims description 8
- 208000029028 brain injury Diseases 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 6
- 206010005052 Bladder irritation Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 5
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 4
- 208000020629 overactive bladder Diseases 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- FYIIKHJFVLTAFI-UHFFFAOYSA-N n-(3-fluoropyridin-4-yl)-3-methyl-n-propylindol-1-amine;hydrochloride Chemical compound Cl.C1=C(C)C2=CC=CC=C2N1N(CCC)C1=CC=NC=C1F FYIIKHJFVLTAFI-UHFFFAOYSA-N 0.000 description 63
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 55
- 229960004979 fampridine Drugs 0.000 description 45
- 241000700159 Rattus Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 29
- 239000003981 vehicle Substances 0.000 description 24
- 230000006378 damage Effects 0.000 description 21
- 230000006872 improvement Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 210000000278 spinal cord Anatomy 0.000 description 12
- 206010012305 Demyelination Diseases 0.000 description 11
- 208000030886 Traumatic Brain injury Diseases 0.000 description 11
- 238000000540 analysis of variance Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000006386 Myelin Proteins Human genes 0.000 description 9
- 108010083674 Myelin Proteins Proteins 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000005012 myelin Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 244000102216 Crateva tapia Species 0.000 description 8
- 235000003495 Crateva tapia Nutrition 0.000 description 8
- 102000018674 Sodium Channels Human genes 0.000 description 8
- 108010052164 Sodium Channels Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000009529 traumatic brain injury Effects 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 230000036982 action potential Effects 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 6
- 229950009831 methylprednisolone succinate Drugs 0.000 description 6
- 239000003450 potassium channel blocker Substances 0.000 description 6
- 210000003625 skull Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 5
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000028161 membrane depolarization Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000007658 neurological function Effects 0.000 description 5
- 230000003957 neurotransmitter release Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000003195 sodium channel blocking agent Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000033952 Paralysis flaccid Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000009227 behaviour therapy Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000028331 flaccid paralysis Diseases 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010069632 Bladder dysfunction Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000025962 Crush injury Diseases 0.000 description 3
- 241001269524 Dura Species 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010041549 Spinal cord compression Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 3
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 238000002684 laminectomy Methods 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 229960002036 phenytoin Drugs 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 208000011403 Alexander disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000018652 Closed Head injury Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- 208000028361 Penetrating Head injury Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000023105 myelination Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229960004181 riluzole Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- OSLGUGPHJWPLED-UHFFFAOYSA-N [O].[O-][N+]#N Chemical compound [O].[O-][N+]#N OSLGUGPHJWPLED-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940105596 baytril Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001966 cerebroprotective effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000002397 epileptogenic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009520 penetrating brain damage Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 230000000216 proconvulsive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229940048278 septra Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26884601P | 2001-02-15 | 2001-02-15 | |
| GBGB0119435.6A GB0119435D0 (en) | 2001-02-15 | 2001-08-09 | Method of treating of demyelinating diseases or conditions |
| PCT/US2002/005501 WO2002064126A2 (en) | 2001-02-15 | 2002-02-14 | Method of treating of demyelinating diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030652A2 true HRP20030652A2 (en) | 2005-06-30 |
Family
ID=23024747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030652A HRP20030652A2 (en) | 2001-02-15 | 2003-08-13 | Method of treating of demyelinating diseases or conditions |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US6967210B2 (ru) |
| EP (1) | EP1368031A2 (ru) |
| JP (3) | JP2004518711A (ru) |
| KR (3) | KR100951540B1 (ru) |
| CN (2) | CN1529598A (ru) |
| AP (1) | AP1749A (ru) |
| AR (1) | AR035750A1 (ru) |
| AU (3) | AU2002247200B9 (ru) |
| BR (1) | BR0207272A (ru) |
| CA (1) | CA2438712A1 (ru) |
| CO (1) | CO5390085A1 (ru) |
| CR (1) | CR7023A (ru) |
| CZ (1) | CZ20032172A3 (ru) |
| EA (2) | EA011319B1 (ru) |
| EC (1) | ECSP024218A (ru) |
| EE (1) | EE200300363A (ru) |
| GB (1) | GB0119435D0 (ru) |
| HK (1) | HK1080361B (ru) |
| HR (1) | HRP20030652A2 (ru) |
| HU (1) | HUP0303203A3 (ru) |
| IL (2) | IL157341A0 (ru) |
| MA (1) | MA26152A1 (ru) |
| ME (1) | MEP21208A (ru) |
| MX (1) | MXPA03006110A (ru) |
| MY (1) | MY157745A (ru) |
| NO (1) | NO20033622L (ru) |
| NZ (4) | NZ556697A (ru) |
| OA (1) | OA12549A (ru) |
| PA (1) | PA8540101A1 (ru) |
| PE (1) | PE20040175A1 (ru) |
| PL (1) | PL363638A1 (ru) |
| SG (1) | SG134170A1 (ru) |
| SK (1) | SK10392003A3 (ru) |
| TR (4) | TR200800693T2 (ru) |
| TW (1) | TWI325319B (ru) |
| UA (2) | UA80394C2 (ru) |
| WO (1) | WO2002064126A2 (ru) |
| YU (1) | YU62903A (ru) |
| ZA (1) | ZA200306124B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
| EP1480631B1 (en) * | 2002-12-20 | 2007-08-01 | Dynogen Pharmaceuticals Inc. | Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators |
| WO2004066990A2 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
| KR100742001B1 (ko) * | 2003-03-21 | 2007-07-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법 |
| GT200500063A (es) * | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| GB0510164D0 (en) * | 2005-04-28 | 2005-06-22 | Paradigm Therapeutics Ltd | Ion channel |
| FR2892022B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene Sa | Traitement des symptomes de l'irritation de la vessie |
| FR2892021B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene | Traitement de l'incontinence urinaire d'effort et mixte |
| US8420593B1 (en) * | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| DE102008044844B4 (de) * | 2008-08-28 | 2018-08-30 | Siemens Healthcare Gmbh | Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes |
| CN102822979B (zh) * | 2010-03-26 | 2015-08-26 | 株式会社半导体能源研究所 | 半导体器件 |
| WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
| US20130030025A1 (en) * | 2011-01-28 | 2013-01-31 | Wessel Thomas C | Use of potassium channel blockers to treat cerebral palsy |
| TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2019126643A1 (en) * | 2017-12-22 | 2019-06-27 | Massachusetts Institute Of Technology | Compositions and methods for williams syndrome (ws) therapy |
| CA3207205A1 (en) * | 2021-01-20 | 2022-07-28 | Rush University Medical Center | Improved treatment for globoid cell leukodsytrophy or krabbe disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4970218A (en) * | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| DE69016531T2 (de) * | 1989-08-02 | 1995-07-06 | Hoechst Roussel Pharma | 2,3-Dihydro-1-(pyridinylamino)-indole, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel. |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
| US5459274A (en) * | 1994-05-13 | 1995-10-17 | Hoechst-Roussel Pharmaceuticals Inc. | Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines |
| US5565475A (en) * | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
| EP0731108A1 (en) * | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
| FR2754147B1 (fr) | 1996-10-03 | 2000-02-04 | Mbh Technologies Sa | Installation et procede pour le traitement de carcasses |
| PT1056754E (pt) * | 1998-01-29 | 2004-03-31 | Bristol Myers Squibb Co | Derivados fosfatados de 1,3,4-oxadiazolona de diarilo |
| US6544976B1 (en) * | 1999-07-09 | 2003-04-08 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
-
2002
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/en active Application Filing
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active IP Right Cessation
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Application Discontinuation
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active IP Right Cessation
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 CA CA002438712A patent/CA2438712A1/en not_active Abandoned
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 EP EP02714974A patent/EP1368031A2/en not_active Withdrawn
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
-
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-13 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
-
2004
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
-
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
-
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
-
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7534803B2 (en) | Method of treating demyelinating diseases or conditions | |
| AU2002247200A1 (en) | Method of treating of demyelinating diseases or conditions | |
| DE3530767C2 (ru) | ||
| EP3512512A1 (en) | Treatment of multiple sclerosis with chs-131 | |
| Ishida et al. | Comparing the anticonvulsive effects of dapsone on amygdala‐kindled seizures and hippocampal‐kindled seizures in rats | |
| KR20060103335A (ko) | 불면증 치료를 위한 가복사돌의 용도 | |
| CZ312894A3 (en) | Use of isethionate of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for preparing a medicament used for treating and prevention of dependence, tolerance and response to drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20100213 Year of fee payment: 9 |
|
| OBST | Application withdrawn |